Physician profile
Patrick Brown
NPI 1689801789
$5,577.84
in general payments reported to CMS, 2019-2025
22 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $250 · 2021: $212 · 2022: $443 · 2023: $1,467 · 2024: $1,479 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.05 |
| Education | $380.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $766.55 | 2020-2025 | Dupixent |
| Abbvie INC. | $728.33 | 2020-2025 | Skyrizi |
| Janssen Biotech, INC. | $668.87 | 2020-2025 | Tremfya |
| Pfizer INC. | $572.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $567.50 | 2020-2025 | |
| Leo Pharma INC. | $479.91 | 2023-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $280.40 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $245.39 | 2020-2025 | Odomzo, Blu-U |
| Ucb, INC. | $227.33 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $214.74 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $201.10 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $178.92 | 2020-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $89.33 | 2020-2025 | Ebglyss, Taltz |
| Strata Skin Sciences, INC. | $86.65 | 2023-2025 | Xtrac |
| Amgen INC. | $76.50 | 2022-2024 | Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $59.52 | 2022 | |
| Elekta, INC. | $34.36 | 2024 | Elekta Medical Linear Accelerator |
| Biofrontera INC. | $28.06 | 2021 | |
| Organon LLC | $19.46 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $18.79 | 2021 | |
| Genzyme Corporation | $18.36 | 2020 | |
| Verrica Pharmaceuticals INC. | $15.29 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.